Crucial Fact

  • Her favourite word was fact.

Last in Parliament November 2005, as Liberal MP for Edmonton Centre (Alberta)

Lost her last election, in 2006, with 39% of the vote.

Statements in the House

Health May 27th, 2003

Mr. Speaker, there is no mixed message. At the outset we indicated that we would be using different technologies. On the basis of pilot projects we would be sharing the results of those different technologies not only here at home but with the WHO and other countries.

If in fact it is discovered that one particular technology does not work as effectively for a reason than some others, we will ensure that the technology is replaced by another one which is less intrusive.

However, please let me clarify for the hon. member that we have no intention of removing the number of scanners we presently have at Pearson and Vancouver airports.

Bovine Spongiform Encephalopathy May 26th, 2003

Mr. Speaker, thank you for this opportunity to speak on such an important issue that concerns us all this evening.

My first words this evening are for the cattle ranchers and the beef industry as a whole in our country. As a member of Parliament from Alberta, I have witnessed many selfless acts by these remarkable people in the past week. Their interest in the issue of food safety and concern about BSE have been longstanding and well documented.

We all know no one is more optimistic than an Alberta farmer. Now we also know of their resolute spirit and willingness to deal with challenges both large and small. After the events of this past week, there is little doubt that food safety is a rancher's number one priority. The dedication of farmers and ranchers to ensuring quality and safety represents Canadians' first line of defence.

I would like to thank our beef producers for their steadfastness at this difficult time. We respect and support their efforts and know they will be part of future solutions.

Health Canada and the Government of Canada as a whole also place the utmost priority on ensuring the health and safety of Canadians.

Let me reinforce the fact that the information available to date suggests that we are dealing with a single case: one cow infected with BSE. I cannot stress often enough that this cow did not enter the human food supply.

The risks to human health at this time are very low, virtually non-existent. We have no information that would lead us to suggest that Canadians should modify their food choices. I am confident in stating that the Canadian food supply is safe.

Of course the confirmation of the single case of BSE is a concern for everyone involved in food protection and food safety, but let there be no doubt about the resolve of the government to ensure that BSE does not become part of the Canadian agricultural landscape.

Many lessons have been learned from the United Kingdom and the European experiences. Health Canada, Agriculture Canada and the Canadian Food Inspection Agency all have been proactive on numerous policy fronts to ensure the safety of the Canadian food supply.

Based on what we learn in the ongoing BSE investigation, there is little doubt that Health Canada and our partners in food safety will make further enhancements to our food safety policy.

Let me highlight some of the measures that the government has taken in the past few years. Canada prohibits importation of beef and beef products from countries not designated as BSE free. Since 1997, Canada has banned the feeding of rendered protein products from ruminant animals, such as cattle, sheep, goats, bison, deer and elk, to other ruminants. Exposure to BSE contaminated feed is considered to be the largest risk factor for the spread of BSE in cattle. This measure is therefore an extremely important part of our strategy.

In addition, we will continue to protect the integrity of Canada's human blood system in light of recent events. I would like to note that blood donations have been prohibited for a number of years from anyone who has spent significant periods of time in countries with substantial occurrences of BSE.

It is important to stress that the discovery of the single case of BSE in Canada does not affect Canadians' ability to donate blood. Careful monitoring will ensure the safety of Canada's blood supply.

Health Canada is also closely monitoring the situation as it relates to the use of rendered animal products as source materials for vaccines, cosmetics and biological products.

The government takes the threat of BSE very seriously. We are aware of the potential impacts in terms of human health and on the Canadian economy.

Even though we are in the midst of an extremely important investigation, we should not lose sight of the important work that has already been done by our public health and food inspection personnel. People are working around the clock to get to the bottom of the issue and we all owe them a very great vote of thanks.

Let me assure Canadians that we will do everything necessary in the future to reassure our ranchers, farmers, trading partners and consumers that Canadian beef is safe and that our food safety net exceeds international standards.

Health Canada will continue to work in support of the Canadian Food Inspection Agency in its investigation of the one confirmed BSE case. As I have said, current evidence suggests the risk to human health appears to be very low, almost non-existent, infinitesimal, very small indeed.

Is there more to do with respect to our food safety policy? Yes, there is. Will we do what is necessary to restore confidence? Yes, we will. By working together with ranchers, beef processors, exporters, food inspection authorities, health departments, provincial governments, our international trading partners and other stakeholders, I am confident that Canada's food safety net will be one of the very safest in the world. It will continue to be one of the very safest in the world.

Mr. Speaker, I am thankful to have participated in this important debate this evening and I should have indicated at the outset that I am splitting my time with the hon. member for Pontiac—Gatineau—Labelle.

Question No. 198 May 26th, 2003

(a) It does not take significantly longer to review and approve a pesticide in Canada as compared to the United States. In fact, for new active ingredient submissions, the review and approval time is shorter in Canada. It may seem to take longer in Canada because historically most companies submit applications for registration in Canada long after submitting an application for registration in the United States. The result of this company practice has been that a number of new pesticide active ingredients and the related end use products are available on the U.S. market before they come to the Canadian market. The Pest Management Regulatory Agency, PMRA, has addressed this problem through implementation of joint review programs with the U.S. Environmental Protection Agency, EPA . One of the goals of the joint review process and other work sharing initiatives with the EPA has been to make the new products available to users in both countries at the same time. The North American Milestone Report may be found at: http://www.hc-sc.gc.ca/pmraarla/english/pdf/-nafta/docs/naftawgrep-e.pdf.

(b) There is no specific part of the approval process that can be considered a ‘roadblock’.

(c) The step by step description of the approval process is contained in the PMRA publication 96-01 Management of Submissions Policy, MOSP, found on http://www.hc-sc.gc.ca/pmra-arla/english/pdf/pro/pro9601-e.pdf. In general there are five steps: verification, screening, review, public consultation/final decision, and verification of final label. The quality of a submission has a major impact on the length of time it takes a submission to proceed through the submission examination process. For example, a high quality, ideal submission for a new active ingredient has a timeline of 737 days or less. For a submission of the poorest quality, there are seven possible points in the process where the applicant has the opportunity to provide missing data, missing fees and/or corrected labels. The PMRA requires time to screen and/or review the additional information submitted to correct the deficiency. For these poor quality submissions, up to 1,912 days may be added to the submission examination process depending on which of the 7 delays are needed by the applicant. Only 6% of the category A submissions registered over the period from 1997-2002 have been ideal submissions. Category A submissions include new active ingredients and companion end use products and/or manufacturing use products, or import maximum residue limits, MRLs, for a new active ingredient, or major new uses (addition of a new use-site category (see response to question d). 94% of the category A submissions registered in this period have had quality problems requiring the use of at least one of the seven delays resulting in additional time being added to the 737 day ideal submission target. PMRA has developed and held training courses and has worked with applicants to assist them in putting together better quality submissions. Through pre-submission consultations and a number of guidelines, the applicant is provided with details of what is required to make a complete submission.

(d) The average length of time to register a pesticide depends on the complexity of each of type of submission. In Canada, for major new active ingredient pesticides, the average time to completion, including the screening and review components, in 2001-02 was 23 months; whereas in the United States, based on the information available from the EPA, in 2001 it was 38 months on average. In 2000-01 the average time to completion in Canada for new active ingredient submissions was 21 months while in the United States in 2000 it was 27 months.

The length of time for each step varies depending on the submission category and subcategory. For category A submissions, which are the most complex and are for new active ingredients or major new uses, there can be eight different sets of performance standards depending on whether the submission is standard or priority or chemical or microbial or reduced risk or a pheromone. For submissions subject to the MOSP, (see response to question c) the typical standard category A submissions registered in 2000-01 had an average verification time of 6 days, first screening time of 49 days, review time of 432 days and first final label verification of 29 days. For 2001-02 the times were 7, 65, 515 and 27 respectively. As part of the MOSP, the final step and end of the review stage for category A submissions is the release of a proposed regulatory decision document, PRDD, for public consultation. For those registered category A submissions that had a public consultation, the public consultation time was always 45 days and the average time for final decision was 32 days. Please note that PRDDs are not currently required by regs but will be required by the new act.

(e) For category A standard submissions, the PMRA targets to complete the review portion of the submission, i.e. after all deficiencies have been addressed by the company, in 18 months (550 days) for traditional chemicals, and 15 months (465 days) for reduced risk chemicals. In 2001- 02 PMRA met its performance target for these submissions. The ideal target length of time for the typical standard category A submission is 7 days for verification, 45 days for screening, 550 days for review, 45 days for public consultation/45 days for final decision, and 45 days for final label verification. For standard category A submissions, subject to the MOSP and excluding deviations, registered/ rejected/withdrawn in 2001-02 that were screened and the review completed, the PMRA met the review performance standard of 550 days on 94% of the submissions.

(f) The new ombudsperson has facilitated increased communication between growers, the PMRA, and Agriculture and Agri-Food Canada to ensure the data requirements for approvals are met and has helped streamline the processing of submissions. In 2002-03 PMRA approved more than 450 minor uses which was more than double that of any of the previous years.

Health May 26th, 2003

Mr. Speaker, we have been in constant contact with the WHO since the announcement last week by Ontario public health officials in relation to this latest cluster.

I would like to point out to the hon. member that as of this morning the WHO is fully aware of not only the number of probable cases identified by public health officials in Ontario but of our screening procedures and, as the WHO has stated throughout, it has no problem with them.

Health May 26th, 2003

Mr. Speaker, nobody is blaming airport authorities and I certainly have not blamed airport authorities.

In fact, we are working with airport authorities to determine how best to implement our enhanced screening measures. As I have indicated, we now have thermal scanners at both Pearson and Vancouver International Airports screening both inbound and outbound passengers.

We are working with the airlines to ensure that passengers coming especially from affected areas not only provide us with travel locator information, but fill in a questionnaire, answering pertinent questions regarding where they have been and whether they have been in close contact with SARS-infected individuals or--

Health May 26th, 2003

Mr. Speaker, there has been no delay. In fact, as I have said throughout this entire situation, we were one of the first nations that responded, on the basis of risk assessment, to WHO recommendations many weeks ago. Those screening procedures have been strengthened and they continue to be strengthened.

The opposition has, for example, talked about thermal scanners, which everybody should be fully aware are no magic bullet. In fact, we have thermal scanners up and working for both inbound and outbound passengers on a pilot project basis at Vancouver and Pearson. We are also heightening other forms of screening at both Vancouver and Pearson, and will in--

Canadian Institutes of Health Research May 15th, 2003

Mr. Speaker, the institute has no agenda of its own in the sense that it has made it very plain that it is well aware of the legislation before the Parliament of Canada. It has indicated that if there are any inconsistencies between its guidelines, as developed by its oversight committee, and the legislation, the legislation will take precedence. It is very simple.

Canadian Institutes of Health Research May 15th, 2003

Mr. Speaker, as the hon. member is well aware, we have been debating Bill C-13 in the House for some time now and that deals with, among other things, embryonic stem cell research. I would encourage all parliamentarians to pass this legislation as quickly as possible.

The CIHR is a body that operates at arm's length from the government. Last April it indicated it would not proceed with stem cell research for a one year, or 12 month period, whereupon it would put in place a steering committee which would then, at some time in the future, receive applications that would potentially deal with embryonic stem cell research.

As I understand it, it is in the process of putting that-

Health May 14th, 2003

Mr. Speaker, as the Prime Minister indicated earlier during question period, after a conference call today with Health Canada officials and health officials from Ontario, the WHO agreed to remove Toronto from its list of SARS affected regions.

This is yet another vote of confidence in Canada, showing that SARS has been controlled and that it is safe to travel to Toronto. It reflects the positive outcome of cooperation among health officials and authorities at all levels of government.

I too want to recognize the work of front line nurses, doctors and health authorities in Toronto, as well as the many Health Canada officials who worked around the clock to battle--

Health May 14th, 2003

Mr. Speaker, it is very clear to the government that 13 provincial and territorial jurisdictions, including all Canadians, stand firmly behind the first ministers accord.

In fact, 34.8 billion new dollars will help insure that provinces and territories are able to deliver a publicly financed, high quality health care system that is based upon the fundamental values shared by all Canadians. There is no question or doubt about that.